The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 40 results:
Author Title Type [ Year(Asc)]
Filters: Author is Stavropoulos, Konstantinos  [Clear All Filters]
2017
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. J Clin Hypertens (Greenwich). 19(12), 1336-1338.
Imprialos, K. P., Stavropoulos K., Doumas M., Karagiannis A., & Athyros V. G. (2017).  The effect of SGLT2 inhibitors on cardiovascular events and renal function.. Expert Rev Clin Pharmacol. 10(11), 1251-1261.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Liraglutide and Renal Outcomes in Type 2 Diabetes.. N Engl J Med. 377(22), 2196.
Faselis, C., Boutari C., Doumas M., Imprialos K., Stavropoulos K., & Kokkinos P. (2017).  Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.. Curr Pharm Des. 23(10), 1540-1550.
Doumas, M., Stavropoulos K., & Imprialos K. (2017).  Obstructive sleep apnea, hypertension, and fibrin clot properties: a novel pathogenetic link with cardiovascular disease?. J Hypertens. 35(5), 950-952.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med. 377(25), 2502.
Imprialos, K., Faselis C., Boutari C., Stavropoulos K., Athyros V., Karagiannis A., et al. (2017).  SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.. Curr Pharm Des. 23(10), 1510-1521.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., & Karagiannis A. I. (2017).  Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 88(3), 249-253.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters.. JAMA Intern Med. 177(9), 1393.
2016
Boutari, C., Stavropoulos K., Imprialos K. P., Petidis K., & Doumas M. (2016).  Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. Am J Hypertens. 29(5), 662.
Stavropoulos, K., Imprialos K. P., Boutari C., Athyros V. G., & Karagiannis A. I. (2016).  Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. J Clin Hypertens (Greenwich). 18(10), 1073.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., Athyros V. G., & Karagiannis A. I. (2016).  Current challenges in antihypertensive treatment in the elderly.. Pol Arch Med Wewn. 126(7-8), 540-51.
Imprialos, K., Boutari C., Stavropoulos K., Doumas M., & Karagiannis A. I. (2016).  Depression in hypertensive patients: the role of comorbidities.. J Hypertens. 34(7), 1441.
Boutari, C., Stavropoulos K., Imprialos K., Doumas M., & Karagiannis A. (2016).  PATHWAY-2: spironolactone for resistant hypertension.. Lancet. 387(10026), 1371-1372.
Imprialos, K. P., Boutari C., Stavropoulos K., Sampani E., & Karagiannis A. I. (2016).  Renin-Angiotensin System Inhibitors: Do They Have the Same Impact at All Ages?. J Clin Hypertens (Greenwich). 18(8), 828.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.